In our study, we hypothesized that bevacizumab affects the antitumor activity of erlotinib and the available concentration of erlotinib in vivo depending on the levels of VEGF expression in NSCLC cells. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.